Serum S100B Protein in Medication-Free Schizophrenic Patients

ABSTRACT

OBJECTIVES: Previous studies have suggested that S100B protein play an important role in the pathogenesis and progress of schizophrenia. In the present study, we evaluate the serum levels of S100B in the patients with schizophrenia, and compare them with those of healthy controls. METHOD: The serum S100B levels were measured by lectrochemiluminescence immunoassay in 21 schizophrenic patients(8 males, 13 females) and 27 normal controls(11 males, 16 females). The Positive and Negative Syndrome Scale(PANSS) was used to evaluate the symptoms of the patients with schizophrenia, and the correlation between PANSS subscale scores and serum S100B levels was examined. RESULTS: No significant difference was found between the serum S100B levels of the schizophrenic patients(0.074+/-0.039ng/ml) and those of the normal controls(0.072+/-0.030ng/ml)(p=0.925). Correlationships between the high serum S100B level with high negative symptom scores(p=0.065) or with the low positive symptom scores(p=0.080) did not exist. CONCLUSION: The relation between serum S100B level and schizophrenia was not found in the present study. However, to confirm this result, further studies, such as measurement of S100 protein level in CSF, postmortem study, long-term follow-up study, and studies with other neurotrophic proteins are needed.